Brief: Exelixis And Natera To Collaborate On Stellar-316, A Phase 3 Pivotal Trial Of Zanzalintinib
07/01/2026 14:07
Jan 7 (Reuters) - Exelixis Inc EXEL.O: EXELIXIS AND NATERA TO COLLABORATE ON STELLAR-316, A PHASE 3 PIVOTAL TRIAL OF ZANZALINTINIB FOR PATIENTS WITH COLORECTAL CANCER EXELIXIS INC - EXPECTS TO INITIATE STELLAR-316 IN MID-2026 Source text: ID:nBwbBkhrRa Further company coverage: EXEL.O ((Reuters.Briefs@thomsonreuters.com;))